Moberg Pharma
36.5 SEK -2.82%5 investors are following this company
Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MOB
Daily low / high price
36.5 / 39
SEK
Market cap
1.75B SEK
Turnover
11.96M SEK
Volume
317K
Latest videos
Financial calendar
Interim report
13.08.2024
Interim report
12.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Östersjöstiftelsen | 11.5 % | 11.5 % |
Avanza Pension | 6.4 % | 6.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools